ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1787

Does Age At Disease Onset Influence Disease Activity and Function In Rheumatoid Arthritis Patients? Results From The Ontario Best Practices Research Initiative (OBRI) Registry

Thanu Nadarajah1, Binu Jacob2, Pooneh Akhavan3, Bindee Kuriya4, Edward C. Keystone5 and Claire Bombardier6, 1Department of Medicine, University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto General Research Institute, Toronto, ON, Canada, 3Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6Rheumatology, University of Toronto, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Aging, Disease Activity, functional status and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease Course in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The population of elderly individuals with rheumatoid arthritis (RA) is increasing. The aim of this study was to assess whether age at disease onset affects disease activity and functional outcome in patients with RA.  We hypothesized that patients with elderly-onset RA (EORA) would have more severe disease and higher disability compared to younger-onset RA (YORA) patients.

Methods: All patients enrolled in the Ontario Best Practices Research Initiative (OBRI), a clinical registry of early and established RA patients followed in routine care, were included in the study (N= 1981). Patients were categorized as EORA if their disease onset was ³ 60 years of age (N=1516) and as YORA if disease onset occurred before 60 years (N=465). Outcomes assessed were disease activity (measured by Disease Activity Score 28 [DAS28]) and function (assessed by Health Assessment Questionnaire [HAQ]) at entry into the registry.  Differences between two groups were compared using chi-square test and t-test. Separate linear regression models, adjusted for gender and disease duration were performed, with p <0.05 considered statistically significant.

Results: The mean (SD) age of patients was 57.4 (12.9) years. The mean (SD) disease duration in the group was 8.5 (9.4) years. EORA patients were less likely to be rheumatoid factor and anti-citrullinated protein antibody positive (p<0.05).  At entry into the registry, EORA patients were more likely to be on disease-modifying agents (79.4% vs. 66.1%, p<0.001) and steroids (27.4% vs. 22.9%, p=0.05), and less likely to be taking biologic therapy (12.1% vs. 25.7%, p<0.001) compared to YORA patients.  Mean DAS28 scores were significantly higher among EORA patients compared to those with YORA (4.6 vs. 4.3, p=0.002).  In a stratified analysis, this association was seen for those with early disease (< 2 years) but not for longer disease duration (Table 1). There was a non-significant trend towards higher HAQ scores among EORA patients compared to YORA patients. In a regression analysis with disease duration as a continuous variable, there was a significant association between EORA and higher disease activity and greater disability (p<0.05).

Table 1: Mean DAS28 and HAQ scores at entry into OBRI, stratified by age at disease onset and disease duration

Disease Duration

Mean DAS28 score

Mean HAQ score

Age at disease onset <60 years

Age at disease onset ³ 60 years

P value

(adjusted for disease duration)

Age at disease onset <60 years

Age at disease onset

³ 60 years

P value

(adjusted for disease duration)

< 2 years

4.47

4.92

0.001

1.07

1.18

0.098

2 – 5 years

4.18

4.25

0.65

1.14

1.12

0.743

> 5 years

4.35

4.35

0.99

1.23

1.41

0.054

Conclusion: Research in the area of EORA has produced mixed results in terms of disease activity and functional disability. Our study demonstrates that older age at disease onset is associated with greater disease activity and functional disability at entry into OBRI. Disease duration appears to influence these outcomes. Further study is required to evaluate which components of the DAS28 may differ among EORA vs. YORA and what drives these potential differences. Furthermore, evaluating the role of factors including comorbidities is necessary to understand the reasons for higher disease activity and poor functional outcome among patients with EORA. 


Disclosure:

T. Nadarajah,

OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), the Ontario Ministry of Health and unrestricted grants from: Abbvie, Amgen, Bristol Myers Squibb, Pfizer, UCB, Janssen and Roche.,

2;

B. Jacob,

OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), the Ontario Ministry of Health and unrestricted grants from: Abbvie, Amgen, Bristol Myers Squibb, Pfizer, UCB, Janssen and Roche.,

2;

P. Akhavan,

OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), the Ontario Ministry of Health and unrestricted grants from: Abbvie, Amgen, Bristol Myers Squibb, Pfizer, UCB, Janssen and Roche.,

2;

B. Kuriya,
None;

E. C. Keystone,
None;

C. Bombardier,

OBRI,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-age-at-disease-onset-influence-disease-activity-and-function-in-rheumatoid-arthritis-patients-results-from-the-ontario-best-practices-research-initiative-obri-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences